2.57
-0.07 (-2.65%)
| Previous Close | 2.64 |
| Open | 2.62 |
| Volume | 13,434 |
| Avg. Volume (3M) | 193,658 |
| Market Cap | 89,140,704 |
| Price / Book | 4.02 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2025 - 12 May 2025 |
| Diluted EPS (TTM) | -1.24 |
| Total Debt/Equity (MRQ) | 47.65% |
| Current Ratio (MRQ) | 5.46 |
| Operating Cash Flow (TTM) | -29.77 M |
| Levered Free Cash Flow (TTM) | -18.34 M |
| Return on Assets (TTM) | -84.19% |
| Return on Equity (TTM) | -409.51% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Achieve Life Sciences, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 2.0 |
| Average | 0.50 |
|
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 9.77% |
| % Held by Institutions | 57.14% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Propel Bio Management, Llc | 31 Dec 2024 | 2,453,092 |
| Sofinnova Investments, Inc. | 31 Dec 2024 | 1,306,482 |
| Long Focus Capital Management, Llc | 31 Dec 2024 | 248,099 |
| Simplify Asset Management Inc. | 31 Dec 2024 | 217,845 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |